lpca Laboratories enters into Technology Transfer Agreement with Omexa Formulary
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
The facility will manufacture tablets, capsules, and injections for the oncology segment
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Subscribe To Our Newsletter & Stay Updated